The Success Story of Dr. Scott Rocklage

Dr. Scott Rocklage is currently a Managing Partner at 5am Ventures which he joined in 2003 as a Venture Partner and rose to its leadership as President the next year. With his 30 plus years’ experience in the healthcare industry, Dr. Scott Rocklage has been able to steer 5am Ventures into success as seen by the FDAs approval of certain drugs administration namely omniscan, cubicin, and teclascan. He has been the CEO and President of several pharmaceutical companies throughout his three-decade long career. Dr. Scotthas also served as chair on several boards including his current positions in Relypsa, Novira, Rennovia, and Cidara among others. The following summary of an interview reveals Dr. Rocklage’s secrets to success and his outlook of entrepreneurship as a whole and read full article.

Unlike most people, Dr. Scott has no typical day or schedule to follow. His days range from working with scientists and on some days he has to prepare for board meetings. Other times, Scott is with the management team of the company working on its portfolio. He cannot say that he does certain things on Mondays or Fridays and what Scott knows.

On the company’s idea, his interactions with entrepreneurs and professionals mainly business executives, scientists, and physicians help him shape the ideas of coming up with acceptable medicines that cover unmet medical needs. One of the trends that is exciting to the doctor is the specific genotypes and mutations that provide a chance to be able to make particular cancer treatment possible. Because of this growing field, lives have been saved, and further improvement is something that the company looks forward to doing and Scott’s lacrosse camp.

It is due to proper time management. Excellent organization skills and prioritizing as well as calendaring that the doctor is able to succeed every day of his life. He also believes that successful companies are those that focus more on people. For instance, he thinks that any business that chooses the right team to work with is on its way to being successful. His secret weapon as an entrepreneur has always been to take calculated risk. His business strategy is to stay true to his business and avoid straying too much from the company’s strengths particularly on the instances that a task appears to be too easy.

Paul Mampilly’s Newsletter is the Fastest Growing in the Financial Industry

For over 20 years, Paul Mampilly has worked on Wall Street for great clients including Kinetics International, Deutsche Bank, and ING. Back in 2009, he won an investment competition organized by the Templeton Foundation. He turned an investment of $50 million into $88 million; a 76% gain without shorting stocks at a time when financial crisis were stiffest. Some time back, he managed a $6 billion hedge fund.

Last year, Paul signed up with Banyan Hill Publishing; an independent research firm and publishing house that focuses on publishing investment newsletters and research advisories. Over the last two years, its subscriber base has grown to more than 200,000 paying members. The headquarters of the company are in Delray Beach, FL. He signed up with Banyan Hill Publishing to begin Profits Unlimited with the aim of helping Main Street Americans achieve profitable investment opportunities. He writes an eight-page newsletter that he mails to his subscribers every month recommending new stocks. Every week, he updates his subscribers on stocks in the portfolio model. More importantly, he monitors the performance of investments on his website.

Instead of investing capital on behalf of his subscribers, they purchase the stocks in their individual brokerage accounts. Paul offers innovative alternatives for his clients and financial advisors. One of his subscribers by the name Alan L says that he has purchased every stock suggested by Paul Mampilly and his investments have always been profitable. Other subscribers praise him saying that they have never come across an outstanding financial advisor like him. Currently, Mampilly’s open portfolio includes stocks of up to 18%, 21%, 31%, and 38%. From the available 13 open positions, 11 are profitable.

Paul Mampilly has had about twenty-five years of investment experience where he has maintained almost every finance job. He has covered healthcare and biotech as a portfolio manager and analyst for major international banks including Bankers Trust, ING, and Deutsche Bank. He has had an impressive list of clients including Swiss private banks, the Templeton Foundation, European aristocracy, and Fortune 500 companies such as Sears and banks such as the Royal Bank of Scotland.

Click here to read more about Paul Mampilly.

See Also http://sovereignsociety.com/meet-the-experts/paul-mampilly/